Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2539)	4/22/2008 10:37:43 PM
From: Biotech Jim	Read Replies (1) \| Respond to of 3158

Rick, I guess you mean that you agree with Birchenough's comments: <With regards to safety and tolerability, the 100mg side effect profile was tolerable and included just 4% (2/49) rates each of diarrhea, upper GI side effects, and hypertension, and there were no cases elevated liver enzymes (ALT >3x ULN). The 10% (5/49) rate of neutropenia observed in the 100mg dose group was manageable with dose reductions and most importantly with no infections.> This was a 12 week efficacy study that appears to be superbly carried out, and M. Weinblatt (former pres of the ACR who brought MTX to the current standard of care)commented on the study in the CC as I recall. Note also that the study was performed on top of MTX. Even though it was stated that the neutropenia was under control, and abated during dose reduction, I would want to see longer term data. One can monitor neutrophils, but I think infections will appear and I think will be problematic. JMO. Only a 12 week study too, so too brief to see the overall risk. I do not see it a a major treatment for ITP as Promacta in my opinion will be used here, and also the AMGN peptibody (though FDA delayed its decision in the face of positive advisory opinion - still an induced antibody possible issue, but that is beyond the scope of this discussion). BJ